Contact this trialFirst, we need to learn more about you.
Immunomodulatory Agent
Ruxolitinib + Steroids + Lenalidomide for Multiple Myeloma
Recruiting1 awardPhase 1
Jacksonville, Florida
This trial tests a combination of ruxolitinib, steroids, and lenalidomide in multiple myeloma patients who are not responding to current treatments. The drugs work together to block cancer growth signals, reduce inflammation, and enhance the immune response. Lenalidomide is an immunomodulatory drug developed from thalidomide, effective in multiple myeloma and approved by the FDA.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service